Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
作者信息
Kulynych J
出版信息
Food Drug Law J. 1999;54(1):127-49.
PMID:11758555
Abstract
摘要
相似文献
1
Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
Food Drug Law J. 1999;54(1):127-49.
2
FDA Modernization Act: implications for oncology.
Oncology (Williston Park). 1998 Nov;12(11A):139-41.
3
Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
Curr Opin Biotechnol. 1999 Jun;10(3):303-6. doi: 10.1016/S0958-1669(99)80054-8.
4
Congress passes FDA reform act: nuclear medicine community stands to gain.
J Nucl Med. 1998 Jan;39(1):15N-16N, 18N.
5
Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist. 1998 May 22;63(99):28301-9.
6
Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov. 2011 Feb;10(2):86. doi: 10.1038/nrd3363.
7
US Senate passes FDA Revitalization Act.
CMAJ. 2007 Jul 3;177(1):23. doi: 10.1503/cmaj.070779.
8
Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
Fed Regist. 2000 Oct 30;65(210):64607-19.
9
FDA: friend or foe?
Med Device Technol. 1996 Nov;7(9):24-30.
10
Nuclear medicine wins decision in FDA PET case.
J Nucl Med. 1997 Dec;38(12):23N.
引用本文的文献
1
Evaluating treatments in health care: the instability of a one-legged stool.
BMC Med Res Methodol. 2011 May 11;11:65. doi: 10.1186/1471-2288-11-65.
Zotero 插件